Guardant Health Inc
NASDAQ:GH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.07
36.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GH stock under the Base Case scenario is 35.5 USD. Compared to the current market price of 30.79 USD, Guardant Health Inc is Undervalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Guardant Health Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Guardant Health Inc
Balance Sheet Decomposition
Guardant Health Inc
Current Assets | 1.2B |
Cash & Short-Term Investments | 895.7m |
Receivables | 88.5m |
Other Current Assets | 242.5m |
Non-Current Assets | 312m |
PP&E | 270.1m |
Intangibles | 10.5m |
Other Non-Current Assets | 31.3m |
Current Liabilities | 197.3m |
Accounts Payable | 15.5m |
Accrued Liabilities | 152.3m |
Other Current Liabilities | 29.6m |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 1.1B |
Other Non-Current Liabilities | 259.6m |
Earnings Waterfall
Guardant Health Inc
Revenue
|
692.3m
USD
|
Cost of Revenue
|
-274.7m
USD
|
Gross Profit
|
417.5m
USD
|
Operating Expenses
|
-939.7m
USD
|
Operating Income
|
-522.1m
USD
|
Other Expenses
|
9.7m
USD
|
Net Income
|
-512.4m
USD
|
Free Cash Flow Analysis
Guardant Health Inc
USD | |
Free Cash Flow | USD |
GH Profitability Score
Profitability Due Diligence
Guardant Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Guardant Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
GH Solvency Score
Solvency Due Diligence
Guardant Health Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Guardant Health Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GH Price Targets Summary
Guardant Health Inc
According to Wall Street analysts, the average 1-year price target for GH is 41.07 USD with a low forecast of 19.19 USD and a high forecast of 52.5 USD.
Dividends
Current shareholder yield for GH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.
Contact
IPO
Employees
Officers
The intrinsic value of one GH stock under the Base Case scenario is 35.5 USD.
Compared to the current market price of 30.79 USD, Guardant Health Inc is Undervalued by 13%.